Neuroventi strengthens partnership with domestic and foreign pharmaceutical bio companies through ‘Bio Korea 2023’

23-05-15

Neuroventi, which is developing new drugs for intractable brain diseases and brain developmental disorders such as autism spectrum disorder and neurodevelopmental disorders such as Fragile X Syndrome, an ASD-like disease, participated in the Bio Korea 2023 partnering event and partnered with domestic and foreign pharmaceutical bio companies. partnering meeting was successfully completed.

'Bio Korea 2023', held from May 10 to 12 at COEX Hall C in Samseong-dong, Seoul, is the largest bio industry event in Korea co-hosted by the Korea Health Industry Development Institute and Chungcheongbuk-do and sponsored by the Ministry of Health and Welfare. Celebrating its 2nd anniversary, it has contributed to promoting the technological level of the Korean biopharmaceutical industry to the world and enhancing the status of the Korean health industry through international trade and exchange promotion.

Under the theme of 'Hyper-Connection Era, Leap to New Growth Innovative Technology', the event operated programs such as academic events (conferences), business partnering, exhibitions, and investment briefings (Invest Fair), with 729 companies from 51 countries participating. It is estimated that more than 22,000 people attended, and in particular, business partnering is more meaningful as domestic and foreign biohealth leading companies participated to seek technology transfer and investment attraction.

Neuroventi acquired orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA) for its autism treatment candidate 'NV01-A02' for the first time in the world in October of last year, and recently received a license from the Korean Intellectual Property Office for the treatment of emotional disorders including autism spectrum disorder. After being notified of the registration of a new substance patent, they are currently preparing to apply for a domestic clinical phase 2 IND (clinical trial plan) for autism spectrum disorder treatment, and based on these achievements, they were able to successfully hold partnering meetings with various pharmaceutical bio companies at this event.

NV01-A02 is a candidate substance discovered through big data analysis by a drug re-creation strategy, and is a candidate substance being developed as a treatment for ASD (autism spectrum disorder) and FXS. NV01-A02 acts on multiple targets and simultaneously and selectively modulates the receptors of several neurotransmitters responsible for regulating social interaction. In addition, as a previously approved drug, it is expected to have a high possibility of clinical success because it has no dependence and no side effects in the central nervous system through optimal regulation of multiple neurotransmitter receptors.

In particular, through this partnering meeting, it was possible to reconfirm the interest of domestic and foreign pharmaceutical bio companies in the company's integrated treatment platform for brain development disorders and central nervous system CDRO service. The provision of non-clinical CDRO services, such as discovery of therapeutic candidates for nervous system disorders, non-clinical research consulting, and research services for non-clinical efficacy evaluation and safety evaluation of candidate substances, is also expected to increase along with the increase in the prevalence and social interest in cranial nerve diseases. .